Previous close | 10.69 |
Open | 0.00 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 0.00 - 0.00 |
52-week range | |
Volume | |
Avg. volume | 122 |
Market cap | N/A |
Beta (5Y monthly) | -1.50 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 06 Nov 2023 - 10 Nov 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Regulus (RGLS) surges as it completes enrollment in the first cohort to evaluate RGLS8429 for kidney disease.
Regulatory and pipeline updates from Moderna (MRNA) and KALA are the key highlights for the biotech sector.
KALA gets Fast Track Designation from the FDA for lead candidate KPI-012 to treat persistent corneal epithelial defects.